title: Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation.
abstract: OBJECTIVE
  To evaluate the pharmacokinetics and use of intravenous human cytomegalovirus immune globulin (CytoGam) in allogeneic bone marrow transplantation (BMT).
  
  
  METHODS
  Prospective, nonrandomized, nonblinded, single-center study.
  
  
  METHODS
  University teaching hospital.
  
  
  METHODS
  Five consecutive patients with hematologic malignancies receiving partially mismatched related donor BMT with a uniform conditioning regimen including total body irradiation and chemotherapy.
  
  
  METHODS
  Serum immunoglobulin and cytomegalovirus (CMV) titers were measured before and 24 hours after the first CytoGam infusion on day -6 during the conditioning regimen.
  
  
  RESULTS
  These levels were measured every 5 days, and a second dose was administered when the CMV titer returned to 25-50% of the 24-hour level. The half-life of CytoGam was approximately 7 days.
  
  
  CONCLUSIONS
  We believe this is the first report of CytoGam's half-life in allogeneic BMT. The information may prove vital in a future study in which the agent's potential beneficial effects can be maximized.
authors.affiliation: Division of Transplantation Medicine, South Carolina Cancer Center, Palmetto Richland Memorial Hospital, University of South Carolina, Columbia 29203, USA.
authors.forename: S Y
authors.initials: SY
authors.lastname: DeRienzo
authors.forename: K Y
authors.initials: KY
authors.lastname: Chiang
authors.forename: W M
authors.initials: WM
authors.lastname: O'Neal
authors.forename: K
authors.initials: K
authors.lastname: Godder
authors.forename: S
authors.initials: S
authors.lastname: Abhyankar
authors.forename: N P
authors.initials: NP
authors.lastname: Christiansen
authors.forename: K D
authors.initials: KD
authors.lastname: Bridges
authors.forename: P J
authors.initials: PJ
authors.lastname: Henslee-Downey
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D005260:Female; D006207:Half-Life; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D014184:Transplantation, Homologous
chemical_list: D016756:Immunoglobulins, Intravenous